We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sage Therapeutics: Breakthrough Status for Depression Drug
Read MoreHide Full Article
Sage Therapeutics, Inc. (SAGE - Free Report) announced that the FDA has granted Breakthrough Therapy designation to its experimental drug SAGE-547, which is being developed for the treatment of postpartum depression (PPD) in women. Shares gained more than 12% in yesterday’s trading session.
Postpartum depression is a severe mental disorder, found to affect women more intensely after childbirth. There are no approved therapies for this disease.
According to information provided by the company in its press release, PPD affects almost 500,000 to 750,000 mothers in the U.S. each year. The status was based on positive top-line results from a placebo-controlled phase II trial (n=21) in women with severe PPD. Data showed that SAGE-547 led to a significant, rapid and durable reduction in depression scores compared with placebo.
The trial met the primary endpoint of a significant reduction in the Hamilton Rating Scale for Depression (HAM-D) score, compared with placebo at 60 hours. The candidate was well tolerated, without having caused any death or serious adverse event. Detailed results will be presented at the 2016 International Marcé Society Biennial Scientific Conference in Melbourne, Australia, on Sep 26–28.
Breakthrough Therapy designation helps expedite the development and review of drugs that are being evaluated for the treatment of serious conditions and where preliminary clinical evidence indicates that the drug may be substantially better than existing treatments on clinically significant endpoint(s).
Sage Therapeutics currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in medical drugs sector include Acerus Pharmaceuticals Corporation , BioSpecifics Technologies Corp. and Corcept Therapeutics Incorporated (CORT - Free Report) . Each of these stocks sports a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand.Click to see them now>>
See More Zacks Research for These Tickers
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Sage Therapeutics: Breakthrough Status for Depression Drug
Sage Therapeutics, Inc. (SAGE - Free Report) announced that the FDA has granted Breakthrough Therapy designation to its experimental drug SAGE-547, which is being developed for the treatment of postpartum depression (PPD) in women. Shares gained more than 12% in yesterday’s trading session.
Postpartum depression is a severe mental disorder, found to affect women more intensely after childbirth. There are no approved therapies for this disease.
According to information provided by the company in its press release, PPD affects almost 500,000 to 750,000 mothers in the U.S. each year. The status was based on positive top-line results from a placebo-controlled phase II trial (n=21) in women with severe PPD. Data showed that SAGE-547 led to a significant, rapid and durable reduction in depression scores compared with placebo.
The trial met the primary endpoint of a significant reduction in the Hamilton Rating Scale for Depression (HAM-D) score, compared with placebo at 60 hours. The candidate was well tolerated, without having caused any death or serious adverse event. Detailed results will be presented at the 2016 International Marcé Society Biennial Scientific Conference in Melbourne, Australia, on Sep 26–28.
Breakthrough Therapy designation helps expedite the development and review of drugs that are being evaluated for the treatment of serious conditions and where preliminary clinical evidence indicates that the drug may be substantially better than existing treatments on clinically significant endpoint(s).
SAGE THERAPEUTC Price
SAGE THERAPEUTC Price | SAGE THERAPEUTC Quote
Zacks Rank & Key Picks
Sage Therapeutics currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in medical drugs sector include Acerus Pharmaceuticals Corporation , BioSpecifics Technologies Corp. and Corcept Therapeutics Incorporated (CORT - Free Report) . Each of these stocks sports a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand.Click to see them now>>